[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"European Breast Cancer Research Association of Surgical Trialists\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":109},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,55,85],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100625456","granulomatous-mastitis-registry-study-100625456",false,"NCT07422870","GRAnulomatous MAstitis REGistry Study","A Retrospective \u002F Prospective Cohort Study to Evaluate the Incidence, Diagnostic Features, Clinical Course and Treatment Strategies in Histologically Confirmed Idiopathic Granulomatous Mastitis","GRAMAREG","Inclusion Criteria:\n\n* Histologically confirmed idiopathic granulomatous mastitis OR cystic neutrophilic granulomatous mastitis by local pathology (minimally invasive biopsy or histological confirmation on surgical specimen)\n* First histological confirmation after January 1, 2015\n* Female or male patients ≥18 years old\n* Signed informed consent form for all patients included in prospective part of the study (patients presenting with idiopathic granulomatous mastitis after activation of the study at Study Site)\n\nExclusion Criteria:\n\n* Patients with suspicion of idiopathic granulomatous mastitis but without histological confirmation\n* Suspicion of OR confirmed secondary granulomatous mastitis due to:\n* Tuberculosis, Sarcoidosis, Fungal infection, Parasitic infection, Foreign body reaction","ALL","18 Years",{"count":20,"type":21},1000,"ESTIMATED","5 Years","OBSERVATIONAL","Idiopathic granulomatous mastitis (IGM) is a rare benign inflammatory breast condition with unknown cause, affecting approximately 2.4 per 100,000 women aged 20-40 years. Patients experience severe local symptoms including pain, redness, and recurrent abscesses that can last weeks to months and often mimic inflammatory breast cancer. Due to its rarity, mostly case reports and case series exist in the literature, leading to limited knowledge about risk factors, optimal treatment strategies, and clinical outcomes.\n\nThe GRAMAREG study is the first European registry for patients with histologically confirmed idiopathic granulomatous mastitis. This retrospective\u002Fprospective observational cohort study aims to systematically evaluate the incidence, diagnostic features, clinical course, treatment strategies, and patient outcomes of this uncommon disease. The study collects both retrospective data (from January 1, 2015 onwards) and prospective data from participating sites across Europe.\n\nAll diagnostic and therapeutic procedures are conducted according to institutional standards in clinical routine, as this is a non-interventional study. Patients in the prospective cohort are followed for up to 5 years to document symptom duration and recurrence rates.",[26,27],"Idiopathic Granulomatous Mastitis","Granulomatous Mastitis",[29,30,31,32,33,34,35,36,37,38,39,40,41],"Idiopathic granulomatous mastitis","IGM","Granulomatous mastitis","Cystic neutrophilic granulomatous mastitis","CNGM","Inflammatory breast disease","Benign breast disease","Chronic mastitis","Non-lactational mastitis","Breast inflammation","Patient registry","Cohort study","granulomatous lobular mastitis","NOT_YET_RECRUITING","2026-02-26",{"date":45,"type":46},"2026-02-27","ACTUAL",{"date":48,"type":21},"2026-04-01",{"date":50,"type":21},"2036-04-01",{"name":52,"class":53},"European Breast Cancer Research Association of Surgical Trialists","NETWORK",2,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":63,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},"100482237","methods-for-localization-of-different-types-of-breast-lesions-100482237","NCT05559411","MEthods for LOcalization of Different Types of Breast Lesions","A Prospective Non-interventional Multicenter Cohort Study to Evaluate Different Imaging-guided Methods for Localization of Non-palpable Malignant Breast Lesions","MELODY","Inclusion Criteria:\n\n* Signed informed consent form\n* Malignant breast lesion requiring breast-conserving surgery and imaging-guided localization (either DCIS or invasive breast cancer; multiple or bilateral lesions and the use of neoadjuvant chemotherapy are allowed)\n* Planned surgical removal of the lesion using one or more of the following imaging-guided localization techniques:\n\n  * Wire-guided localization\n  * Intraoperative ultrasound\n  * Magnetic localization\n  * Radioactive seed localization\n  * Radioguided Occult Lesion Localization (ROLL)\n  * Radar localization\n  * Radiofrequency identification (RFID) tag localization\n  * Ink\u002Fcarbon localization\n* Female \u002F male patients ≥ 18 years old\n\nExclusion Criteria:\n\n* Patients not suitable for surgical treatment\n* Patients requiring mastectomy as first surgery\n* Surgical removal without imaging-guided localization",{"count":64,"type":21},7416,"In the last decades, the proportion of breast cancer (BC) patients receiving breast-conserving surgery has increased steadily, reaching 70-80% in developed countries. Since positive resection margins are strongly associated with local recurrence risk, the goal of breast surgery is the complete tumor removal and most national and international guidelines recommend re-operation, either in form of re-excision or mastectomy, until clear margins have been reached. Re-operation rates vary widely, with population-based studies reporting a range of 15-35%, and the necessity for a second surgery can lead to increased patient anxiety, a delay in start of adjuvant treatment, worse cosmetic outcome and increased complication rates and costs. Therefore, re-operation rate has been included as a quality indicator in several countries.\n\nSeveral imaging-guided techniques have been developed to guide removal of non-palpable breast lesions, the oldest one being preoperative wire placement under ultrasound or mammographic guidance, usually followed by radiography or ultrasound of removed tissue. Newer techniques, such as intraoperative ultrasound (IOUS), radioguided occult lesion localization (ROLL), radioactive seed localization (RSL), radar reflector-localization (RRL), magnetic seed localization (MSL), and radiofrequency identification (RFID) tags have been introduced as an alternative to wire-guided localization (WGL).\n\nTo date, comparative data on the rates of successful lesion removal, negative margins, re-operation rate and patient's comfort depending on the localization technique used are limited. Further, since some of these studies were funded by the manufacturer of the marker examined, a potential bias cannot be excluded. In the vast majority of the available studies, the patient's perspective with regard to discomfort and pain level has not been evaluated.\n\nThe aim of the proposed study is to comparatively evaluate different imaging-guided localization methods used for surgical removal of malignant breast lesions with regard to oncological safety and patient-reported outcomes.",[67],"Breast Cancer",[69,70,71,72,73,74],"breast cancer","non-palpable breast lesion","localization technique","localization device","intraoperative ultrasound","patient-reported outcome","RECRUITING","2025-02-27",{"date":78,"type":46},"2025-03-03",{"date":80,"type":46},"2023-01-01",{"date":82,"type":21},"2026-12",{"name":52,"class":53},1,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":93,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":95,"conditions":96,"keywords":97,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":103,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":84},"100391182","axillary-surgery-after-neoadjuvant-treatment-100391182","NCT04373655","AXillary Surgery After NeoAdjuvant Treatment","A Prospective Multicenter Cohort Study to Evaluate Different Surgical Methods of Axillary Staging (sentinel Lymph Node Biopsy, Targeted Axillary Dissection, Axillary Dissection) in Clinically Node-positive Breast Cancer Patients Treated with Neoadjuvant Chemotherapy","AXSANA","Inclusion Criteria:\n\n* Signed informed consent form\n* Primary invasive breast cancer (confirmed by core biopsy)\n* cN+\n* cT1-4c\n* Scheduled for neoadjuvant systemic therapy\n* Female \u002F male patients ≥ 18 years old\n\nExclusion criteria\n\n* Distant metastasis\n* Recurrent breast cancer\n* Inflammatory breast cancer\n* Extramammary breast cancer\n* Supraclavicular lymph node metastasis\n* Pregnancy\n* Less than 4 cycles of NACT administered\n* Patients not suitable for surgical treatment",{"count":94,"type":21},3000,"The optimal surgical axillary staging technique in patients who convert from the clinically positive to clinically negative lymph node status under neoadjuvant therapy (cN+ → ycN0) remains to be clarified. Different strategies (axillary lymph node dissection, sentinel node biopsy, targeted axillary dissection) are currently used in different countries. A prospective analysis comparing these techniques regarding feasibility, safety, morbidity and surgical effort is urgently needed. Due to high complexity and discordant recommendations, a randomized trial comparing different techniques is hardly feasible. Therefore, the EUBREAST study group decided to initiate a prospective cohort study as an international project that aims at comparatively evaluating data on axillary staging after neoadjuvant therapy.",[67],[69,98,99,100,101,102],"neoadjuvant chemotherapy","axillary lymph node dissection","targeted axillary dissection","target lymph node","sentinel node biopsy",{"date":78,"type":46},{"date":105,"type":46},"2020-04-28",{"date":107,"type":21},"2030-04",{"name":52,"class":53},""]